Health · 22 views
Aficamten trial brings positive news for patients living with non-obstructive hypertrophic cardiomyopathy
Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, according to results presented today in a Hot Line session…
Summary
Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, according to results presented today in a Hot Line session at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patientsContinue reading
- Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar rangeContinue reading
- Wearing headphones during surgery may reduce nausea and vomiting afterwardContinue reading
- Adult ADHD; Encouraging Advance Care Planning; Hospital Closures in the U.S.Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow